Related Experiment Video
Updated: Jun 22, 2025
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Association between inflammatory bowel disease and the risk of parenteral malignancies: A two-sample Mendelian
Peizhu Su1, Yilin Wang1, Huiwen Huang1
1Department of Digestive Disease, The First People's Hospital of Foshan City, Guangdong, P.R. China.
Aim:
Using Mendelian Randomization (MR) analysis to investigate the potential causal association between Inflammatory Bowel Disease (IBD) and the occurrence of parenteral malignancies, in order to provide some reference for the parenteral malignancy prevention in patients with IBD.
Methods:
This was a two-sample MR study based on independent genetic variants strongly linked to IBD selected from the Genome-Wide Association Study (GWAS) meta-analysis carried out by the International Inflammatory Bowel Disease Genetics Consortium (IIBDGC). Parenteral malignancy cases and controls were obtained from the FinnGen consortium and the UK Biobank (UKB) release data. Inverse Variance Weighted (IVW), weighted median, MR-Egger, and strength test (F) were utilized to explore the causal association of IBD with parenteral malignancies. In addition, Cochran's Q statistic was performed to quantify the heterogeneity of Instrumental Variables (IVs).
Results:
The estimates of IVW showed that patients with IBD had higher odds of diffuse large B-cell lymphoma (OR = 1.2450, 95% CI: 1.0311‒1.5034). UC had potential causal associations with non-melanoma skin cancer (all p < 0.05), melanoma (OR = 1.0280, 95% CI: 0.9860‒1.0718), and skin cancer (OR = 1.0004, 95% CI: 1.0001‒1.0006). Also, having CD was associated with higher odds of non-melanoma skin cancer (all p < 0.05) and skin cancer (OR = 1.0287, 95% CI: 1.0022‒1.0559). In addition, results of pleiotropy and heterogeneity tests indicated these results are relatively robust.
Conclusions:
IBD has potential causal associations with diffuse large B-cell lymphoma and skin cancers, which may provide some information on the prevention of parenteral malignancies in patients with IBD. Moreover, further studies are needed to explore the specific mechanisms of the effect of IBD on skin cancers.
Insights
Inflammatory Bowel Disease (IBD) is linked to increased risks of diffuse large B-cell lymphoma and skin cancers. This study used Mendelian Randomization to investigate these associations, informing potential cancer prevention strategies for IBD patients.
Area of Science:
- Genetics
- Epidemiology
- Oncology
Background:
- Inflammatory Bowel Disease (IBD) encompasses chronic conditions like Crohn's disease (CD) and ulcerative colitis (UC).
- The association between IBD and secondary malignancies requires further investigation to inform patient management and prevention strategies.
Purpose of the Study:
- To investigate the potential causal relationship between Inflammatory Bowel Disease (IBD) and the risk of developing parenteral malignancies using Mendelian Randomization (MR).
- To provide insights for the prevention of parenteral malignancies in individuals diagnosed with IBD.
Main Methods:
- A two-sample MR study utilizing genetic variants associated with IBD from the International Inflammatory Bowel Disease Genetics Consortium (IIBDGC).
- Parenteral malignancy data were sourced from the FinnGen consortium and UK Biobank (UKB).
- Analyses employed Inverse Variance Weighted (IVW), weighted median, MR-Egger methods, with heterogeneity assessed by Cochran's Q statistic.
Main Results:
- Mendelian Randomization analysis indicated that IBD is associated with a higher likelihood of diffuse large B-cell lymphoma (OR = 1.2450).
- Ulcerative colitis (UC) showed potential causal links with non-melanoma skin cancer and melanoma.
- Crohn's disease (CD) was associated with increased odds of non-melanoma skin cancer and overall skin cancer.
Conclusions:
- The study suggests potential causal associations between Inflammatory Bowel Disease (IBD) and specific cancers, including diffuse large B-cell lymphoma and various skin cancers.
- Findings may contribute to developing targeted prevention strategies for parenteral malignancies in IBD patients.
- Further research is warranted to elucidate the underlying mechanisms connecting IBD and the development of skin cancers.
Related Concept Videos
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:20Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents